Aim: DMAB is a human monoclonal antibody that binds to RANK ligand to inhibit osteoclast-mediated resorption and is approved to prevent skeletal-related events in pts with bone metastases from solid tumors. DMAB-induced inhibition of bone resorption may impact calcium (Ca) homeostasis, affecting serum Ca levels. This study evaluated the incidence of hypocalcemia and safety parameters of pts with stage 4 or 5D CKD who were administered two subcutaneous (SC) doses of DMAB. Methods: Patients received two 120 mg doses of SC DMAB 28 days apart and were followed until day 113. All pts were required to have controlled secondary hyperparathyroidism and receive oral supplementation of ≥500 mg Ca and 400 IU vitamin D daily. The primary endpoint was the incidence of clinically significant, albumin-adjusted, serum Ca levels <7.0 mg/dL (1.75 mmol/L) or symptomatic hypocalcemia. Data were analyzed with descriptive statistics. Results: 31/32 enrolled pts received 2 DMAB doses (15 stage 4; 16 stage 5D); 1 stage 4 CKD pt received 1 dose before withdrawing consent. 50% of pts were men, 78% white, and the median age was 76 years. The incidence of clinically significant hypocalcemia and adverse events at any point in the study are shown (Table) . The majority (∼97%) of hypocalcemic events were mild to moderate in severity. The mean maximal serum DMAB concentrations were similar between the stage 4 and 5D CKD groups, 10.5 vs 8.17 µg/mL after dose 1 and 16.1 vs 14.5 µg/mL after dose 2. 
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